NeuroStar offers Transcranial Magnetic Stimulation (TMS), a safe and effective treatment for major depressive disorder, obsessive-compulsive disorder, and anxious depression. The treatment is FDA-cleared and is claimed to revitalize inactive synapses in the brain.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

COM:NEUROSTAR

NeuroStar

Last Close

0.84

22/11 21:00

Market Cap

55.50M

Beta: -

Volume Today

291.17K

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics